Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Diabetic Neuropathy Overview | 9 | 1 |
| Therapeutics Development | 10 | 2 |
| Pipeline Products for Diabetic Neuropathy Overview | 10 | 1 |
| Pipeline Products for Diabetic Neuropathy Comparative Analysis | 11 | 1 |
| Diabetic Neuropathy Therapeutics under Development by Companies | 12 | 2 |
| Diabetic Neuropathy Therapeutics under Investigation by Universities/Institutes | 14 | 1 |
| Diabetic Neuropathy Pipeline Products Glance | 15 | 3 |
| Late Stage Products | 15 | 1 |
| Clinical Stage Products | 16 | 1 |
| Early Stage Products | 17 | 1 |
| Diabetic Neuropathy Products under Development by Companies | 18 | 2 |
| Diabetic Neuropathy Products under Investigation by Universities/Institutes | 20 | 1 |
| Diabetic Neuropathy Companies Involved in Therapeutics Development | 21 | 17 |
| Achelios Therapeutics, Inc. | 21 | 1 |
| Araim Pharmaceuticals, Inc. | 22 | 1 |
| Celgene Corporation | 23 | 1 |
| Commence Bio, Inc. | 24 | 1 |
| Glucox Biotech AB | 25 | 1 |
| KPI Therapeutics, Inc. | 26 | 1 |
| Lpath, Inc. | 27 | 1 |
| Medifron DBT Co., Ltd. | 28 | 1 |
| Neuralstem, Inc. | 29 | 1 |
| NovaLead Pharma Pvt. Ltd. | 30 | 1 |
| Novartis AG | 31 | 1 |
| Omeros Corporation | 32 | 1 |
| PhiloGene, Inc. | 33 | 1 |
| Reata Pharmaceuticals, Inc. | 34 | 1 |
| Relief Therapeutics S.A. | 35 | 1 |
| Sucampo Pharmaceuticals, Inc. | 36 | 1 |
| ViroMed Co Ltd | 37 | 1 |
| Diabetic Neuropathy Therapeutics Assessment | 38 | 11 |
| Assessment by Monotherapy Products | 38 | 1 |
| Assessment by Target | 39 | 3 |
| Assessment by Mechanism of Action | 42 | 3 |
| Assessment by Route of Administration | 45 | 2 |
| Assessment by Molecule Type | 47 | 2 |
| Drug Profiles | 49 | 57 |
| atexakin alfa Drug Profile | 49 | 1 |
| benfotiamine Drug Profile | 50 | 1 |
| BNV-222 Drug Profile | 51 | 2 |
| cibinetide Drug Profile | 53 | 3 |
| CMB-200 Drug Profile | 56 | 1 |
| Cyndacel-M Drug Profile | 57 | 1 |
| EMA-401 Drug Profile | 58 | 3 |
| ketoprofen Drug Profile | 61 | 1 |
| Lpathomab Drug Profile | 62 | 3 |
| MDR-652 Drug Profile | 65 | 1 |
| Monoclonal Antibodies to Inhibit MASP-2 for Diabetic Complications and Rheumatoid Arthritis Drug Profile | 66 | 2 |
| ND-07 Drug Profile | 68 | 1 |
| NLP-198 Drug Profile | 69 | 1 |
| NSI-189 Drug Profile | 70 | 5 |
| NSI-566 Drug Profile | 75 | 8 |
| OMS-721 Drug Profile | 83 | 7 |
| PDA-002 Drug Profile | 90 | 1 |
| Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction Drug Profile | 91 | 1 |
| pirenzepine hydrochloride Drug Profile | 92 | 1 |
| Recombinant Protein to Antagonize VEGFR-2 for Oncology and Metabolic Disorders Drug Profile | 93 | 1 |
| RTA-901 Drug Profile | 94 | 1 |
| RTU-1096 Drug Profile | 95 | 1 |
| Small Molecule for Pain Drug Profile | 96 | 1 |
| Small Molecule to Inhibit NOX-4 for Diabetic Neuropathy Drug Profile | 97 | 1 |
| Small Molecules for Diabetic Neuropathy Drug Profile | 98 | 1 |
| Small Molecules to Inhibit Hsp90 for Amyotrophic Lateral Sclerosis and Peripheral Neuropathy Drug Profile | 99 | 1 |
| U-2902 Drug Profile | 100 | 2 |
| VM-202 Drug Profile | 102 | 3 |
| XK-568b Drug Profile | 105 | 1 |
| Diabetic Neuropathy Dormant Projects | 106 | 4 |
| Diabetic Neuropathy Discontinued Products | 110 | 1 |
| Diabetic Neuropathy Product Development Milestones | 111 | 5 |
| Featured News &Press Releases | 111 | 1 |
| Sep 08, 2016: ViroMed proceeding with the World s first phase III gene therapy clinical trial for diabetic peripheral neuropathy | 111 | 1 |
| Jun 27, 2016: VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate, VM202, in Painful Diabetic Peripheral Neuropathy | 111 | 1 |
| Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition | 112 | 2 |
| Sep 23, 2013: Lpath Awarded NIH SBIR Grant for Lpathomab | 114 | 1 |
| Sep 12, 2011: Spinifex Pharmaceuticals Presents New Data On EMA401 In Model Of Diabetic Neuropathy At 21st Annual NEURODIAB Meeting | 114 | 1 |
| Mar 18, 2011: ViroMed Enrolls Final Patient For US VM202-DPN Phase I/II Clinical Trial | 115 | 1 |
| Mar 04, 2009: ViroMed Receives Approval from US FDA for Phase I/II Trial for Diabetic Neuropathy | 115 | 1 |
| Appendix | 116 | 2 |
| Methodology | 116 | 1 |
| Coverage | 116 | 1 |
| Secondary Research | 116 | 1 |
| Primary Research | 116 | 1 |
| Expert Panel Validation | 116 | 1 |
| Contact Us | 116 | 1 |
| Disclaimer | 117 | 1 |